Status:
COMPLETED
The Vascular and Metabolic Effects of Sunitinib in Patients With Metastatic Renal Cell Carcinoma
Lead Sponsor:
Radboud University Medical Center
Collaborating Sponsors:
Dutch Cancer Society
Conditions:
Hypertension
Renal Function
Eligibility:
All Genders
18+ years
Brief Summary
Rationale: The introduction of angiogenesis inhibitors, like sunitinib and bevacizumab, has improved the outcome of patients with several types of cancer remarkably. However, their application is hamp...
Eligibility Criteria
Inclusion
- Subject is able and willing to sign the Informed Consent Form
- Age 18 years or older
- WHO performance status 0-2
- Life expectancy ≥ 12 weeks
- mRCC patients in which the treatment of choice is sunitinib
Exclusion
- Use of corticosteroids
- Any evidence of severe or uncontrolled diseases other than renal cell carcinoma eg, unstable or uncompensated respiratory, cardiac, hepatic or renal disease.
- Known risk of the patient transmitting HIV, hepatitis B or C via infected blood
- Patients being treated with oral anticoagulants if to be included in group A.
Key Trial Info
Start Date :
November 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2013
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT01227213
Start Date
November 1 2010
End Date
November 1 2013
Last Update
October 30 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Radboud University Nijmegen Medical Centre
Nijmegen, Netherlands, 6500HB